Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 12 852 / https://doi.org/10.3332/ecancer.2018.852

Special Issue

Development of an eHealth tool for cancer patients: monitoring psychoemotional aspects with the family resilience (FaRe) questionnaire

In the last decade, clinicians have started to shift from an individualistic perspective of the patient towards family-centred models of care, due to the increasing evidence from research and clinical practice of the crucial role of significant others in determining the patient's adjustment to cancer disease and management. eHealth tools can be considered a means to compensate the services gap and support outpatient care flows. Within the works of the European H2020 iManageCancer project, a review of the literature in the field of family resilience was conducted, in order to determine how to monitor the patient and his/her family's resilience through an eHealth platform. An analysis of existing family resilience questionnaires suggested that no measure was appropriate for cancer patients and their families. For this reason, a new family resilience questionnaire (named FaRe) was developed to screen the patient's and caregiver's psycho-emotional resources. Composed of 24 items, it is divided into four subscales: Communication and Cohesion, Perceived Family Coping, Religiousness and Spirituality, and Perceived Social Support. Embedded in the iManageCancer eHealth platform, it allows users and clinicians to monitor the patient's and the caregivers' resilience throughout the cancer trajectory.

Keywords: Resilience, psychological, family health, telemedicine, neoplasms, health services

Loading Article Metrics ... Please wait

Related articles

Research: Depression and quality of life in patients with breast cancer undergoing chemotherapy and monoclonal antibodies

Abstract | Full Article | PDF Published: 10 Jul 2019 / https://doi.org/10.3332/ecancer.2019.937

Review: Challenges and shifting paradigms in clinical trials in oncology, the case for immunological and targeted therapies

Abstract | Full Article | PDF Published: 05 Jul 2019 / https://doi.org/10.3332/ecancer.2019.936

Research: Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse

Abstract | Full Article | PDF Published: 27 Jun 2019 / https://doi.org/10.3332/ecancer.2019.935

Research: Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy

Abstract | Full Article | PDF Published: 06 Jun 2019 / https://doi.org/10.3332/ecancer.2019.934

Case Report: Two cases of gastric mucosa-associated lymphoid tissue (MALT) lymphoma masquerading as follicular gastritis

Abstract | Full Article | PDF Published: 03 Jun 2019 / https://doi.org/10.3332/ecancer.2019.933



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation